|Hospital:||The Netherlands Cancer Institute|
|Patients: This Phase II study involved 24 patients with malignant pleural mesothelioma; 19 men and 5 women. The median age was 63 years.|
Treatment: The treatment consisted of the drug raltitrexed (tomudex). This agent inhibits the enzyme thymidylate synthase which is involved in the synthesis of DNA.
Toxicity: Grade 3-4 toxicities included anorexia, shortness of breath/dyspnea, hematologic, febrile neutropenia, nausea/vomiting, neurological toxicity, chest pain, pleuritic pain, and cough.
Results: The overall median survival was 7 months.
Support: AstraZeneca provided the drug (Tomudex) free of charge.
Correspondence: P. Baas, MD